Inhaled Versus Intravenous Milrinone for Patients Undergoing Mitral Valve Replacement Surgery

Phase 2

Active, not recruiting

• Conditions: Pulmonary Hypertension; Intravenous Milrinone; Mitral Valve Replacement; Inhaled Milrinone
• Interventions: Drug: Inhaled Milrinone; Drug: IV Milrinone

• Registration Number: NCT05838846
• Lead Sponsor: Menoufia University

Brief Summary

This prospective double blinded randomized study aims to compare the effect of inhaled versus intravenous milrinone on the pulmonary vascular resistance in patients undergoing mitral valve replacement surgery.

The primary outcome is to determine change in pulmonary artery pressure. The secondary outcomes include,

* Incidence of systemic hypotension.

* Hemodynamic affection and need of vasopressors and inotropes.

* Change in pulmonary vascular resistance versus systemic vascular resistance.

* Right ventricular function.

* Duration of mechanical ventilation.

* Need for mechanical circulatory support devices.

* Urine output

* Length of intensive care (ICU) in stay.

As the investigators hypothesize that inhaled milrinone has a selective pulmonary vasodilator effect devoid of the systemic hypotension with the intravenous administration.

Detailed Description

Standard preoperative assessment for cardiac surgery will be done for all patients. Premedication will be given according to standard protocol in our university hospitals as follow bromazepam 3mg oral and ranitidine 150 mg orally in the night-before then another dose of ranitidine 150 mg 2 hours before arrival in operating theatre by small sips of clear liquid.

On arrival to induction room wide bore IV access will be inserted using local anesthetic then arterial cannula in radial artery will be inserted the same manner using local anesthetic then in operating room routine monitoring including a five-lead electrocardiogram, pulse oximeter and invasive blood pressure will be attached.

Anesthesia will be induced with midazolam 0.02 mg/kg and fentanyl 2-5 mcg/kg and muscle relaxation will be achieved by cis-atracurium 0.15 mg/kg. After tracheal intubation, central venous line and transesophageal echocardiography will be inserted, then anesthesia will be maintained throughout the procedure with morphine 20 mcg/kg/min, cis-atracurium 2 mcg/kg/min and sevoflurane 0.4% - 2% MAC. Ventilation will be adjusted to maintain end-tidal carbon dioxide in the range of 30-40 mmHg.

During cardiopulmonary bypass, flow of 2.2 l/min/m2 will be achieved, 20 ml/kg cold blood cardioplegia will be given manually and pressure controlled at 20 - 30 min interval along with hot shot at start of weaning from CPB, temperature will be maintained at 32-34℃ and propofol 1% infusion at rate of 8 - 12ml/hr.

In initial TEE study, baseline measures will be taken assessing left ventricular ejection fraction, and right ventricular hemodynamics represented by right ventricular function measured by \[tricuspid annulus plane systolic excursion, fractional area changes, and right ventricular systolic pressure by doppler\] also, pulmonary vascular resistance and systemic vascular resistance will be calculated, plus patients hemodynamics (mean arterial blood pressure, heart rate) and inotropic score all measures will be recorded.

Study Timeline

• Study Start: 2023-04-01
• Study First Submitted: 2023-04-06
• Study First Submitted QC: 2023-04-19
• Study First Posted: 2023-05-03
• Status Verified: 2024-03
• Last Update Submitted: 2024-03-11
• Last Update Posted: 2024-03-13
• Primary Completion: 2024-10
• Study Completion: 2025-03

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 116

Inclusion Criteria

• Severe mitral regurgitation and moderate or severe pulmonary hypertension

• Scheduled for mitral valve replacement surgery

  Criteria of severe mitral regurgitation:

• Central jet MR >40% LA or holosystolic eccentric jet MR

• Vena contracta ≥ 0.7 cm

• Regurgitant volume ≥60 ml

• Regurgitant fraction ≥50%

• EROA ≥0.40 cm2

  Criteria of moderate and severe pulmonary hypertension:

• Moderate pulmonary hypertension; mean pulmonary artery pressure > 41 mmHg while, severe pulmonary hypertension; mean pulmonary artery pressure > 55 mmHg

• Mean pulmonary artery pressure > 40% of mean systemic blood pressure.

• Mean pulmonary artery pressure approximated from estimated systolic pulmonary artery pressure as following; mPAP= (estimated sPAP X 0.61) ± 2

Read More

Exclusion Criteria

• Patients with multiple valve diseases -other than mitral valve-.
• Hemodynamic instability in the preoperative time (defined as acute requirement for vasoactive support or mechanical device).
• Contraindication to transesophageal echocardiography; esophageal stricture, tumor or diverticulum or active upper gastrointestinal bleeding
• Patients with hepatic or renal dysfunction.
• Patients with coagulopathy.
• Emergency surgeries.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Group A (iMil)	Inhaled Milrinone	Patients will receive 2 doses of inhaled milrinone at the following time points (after sternotomy and after aortic cross clamp off) at dosage of 50 mcg/kg by nebulization, inhaled milrinone will be administered through Aerogen solo with Pro-X controller - continuous mode- attached to ventilator circuit distal to viral/ bacterial heat and moisture exchange filter. Then pulmonary vascular resistance and systemic vascular resistance will be calculated after first dose ended by 2 minutes and after second dose ended by 15 minutes till stabilization of post CPB other variables like temperature and acid-base status, both measurements will be done while using inspired oxygen of 0.80.
Group B (IvMil)	IV Milrinone	Patients will receive intravenous milrinone - started after induction of anesthesia - infusion at dosage of 0.5 mcg/kg/min without loading dose (24), Pulmonary vascular resistance and systemic vascular resistance will be calculated at the same corresponding time points to group A.

Primary Outcome Measures

Name	Time	Method
Change in pulmonary artery pressure	Intraoperative

Secondary Outcome Measures

Name	Time	Method
Incidence of systemic hypotension	Intraoperative and postoperative in ICU (up to 24 hours)
Length of intensive care (ICU) in stay	Intraoperative and postoperative in ICU (up to 24 hours)
Duration of mechanical ventilation	Intraoperative and postoperative in ICU (up to 24 hours)
Urine output	Intraoperative and postoperative in ICU (up to 24 hours)
Pulmonary vascular resistance versus systemic vascular resistance	Intraoperative and postoperative in ICU (up to 24 hours)	Systemic vascular resistance: (MAP-CVP) x 80 / CO; Pulmonary vascular resistance = (MPAP-LAP) X 80 / CO
Hemodynamic affection and need of vasopressors and inotropes.	Intraoperative and postoperative in ICU (up to 24 hours)
Right ventricular function	Intraoperative and postoperative in ICU (up to 24 hours)	Measured by tricuspid annulus plane systolic excursion, fractional area changes, and right ventricular systolic pressure by doppler
Need for mechanical circulatory support devices	Intraoperative and postoperative in ICU (up to 24 hours)

Trial Locations

Locations (1)

Menoufia University Hospitals; 🇪🇬 Shibīn Al Kawm, Menoufia, Egypt